|
시장보고서
상품코드
1890943
종양 혈액검사 시장 : 바이오마커 유형별, 기술별, 임상 응용별, 암 유형별, 최종사용자별, 지역별Tumor Blood Testing Market, By Biomarker Type, By Technology, By Clinical Application, By Cancer Type, By End User, By Geography |
||||||
종양 혈액검사 시장은 2025년에 93억 4,000만 달러로 추정되며, 2032년까지 238억 1,000만 달러에 달할 것으로 예측되고 있습니다. 2025-2032년의 CAGR은 14.3%로 예측되고 있습니다.
| 리포트 내용 | 리포트 상세 | ||
|---|---|---|---|
| 기준연도 : | 2024년 | 2025년 시장 규모 : | 93억 4,000만 달러 |
| 과거 데이터 대상 기간 : | 2020-2024년 | 예측 기간 : | 2025-2032년 |
| 예측 기간인 2025-2032년의 CAGR : | 14.30% | 2032년에서 예측 가치 : | 238억 1,000만 달러 |
세계 종양 혈액 검사 시장은 광범위한 종양 진단 분야에서 혁신적인 부문을 구성하고 있으며, 현대 의료에서 암 감지, 모니터링 및 치료 정책 결정에 대한 접근 방식을 근본적으로 재구성하고 있습니다.
액체생검이라고도 불리는 종양 혈액 검사는 말초 혈액 샘플에 존재하는 순환 종양 세포(CTC), 순환 종양 DNA(ctDNA), 엑소좀, 기타 종양 유래 바이오마커를 분석하는 획기적인 비침습적 진단 기술의 집합체입니다.
이 혁신적인 방법은 기존의 조직 기반 생검에 비해 환자 부담 감소, 시술 위험 감소, 실시간 모니터링 기능, 종양의 이질성을 보다 종합적으로 파악할 수 있는 능력 등 큰 이점을 제공합니다. 이 시장은 암 조기 검진 및 진단부터 치료 선택, 치료 효과 모니터링, 미세 잔존 병변 검출에 이르기까지 다양한 응용 분야를 포괄하고 있습니다.
유전체 시퀀싱 기술의 발전, 인공지능의 통합, 액체생검의 효능을 지원하는 임상적 증거 증가로 종양 혈액 검사 시장은 전례 없는 성장세를 보이고 있습니다. 전 세계 암 유병률 증가와 정밀의료 접근법 및 개인 맞춤형 치료 전략에 대한 수요 증가는 전 세계 다양한 헬스케어 분야에서 시장 확대를 지속적으로 견인하고 있습니다.
시장 역학
세계 종양 혈액 검사 시장의 급속한 확장과 임상 도입을 촉진하는 몇 가지 강력한 촉진요인이 존재합니다. 주요 성장 요인은 전 세계 암 부담 증가에 있습니다. 발병률이 증가함에 따라 조기 발견과 치료 과정을 통한 지속적인 모니터링을 가능하게 하는 보다 효율적이고 접근성이 높으며 환자 친화적인 진단 솔루션이 요구되고 있습니다.
차세대 시퀀싱, 디지털 PCR, 분자 프로파일링 기술 등의 기술 발전으로 액체생검의 민감도와 특이성이 크게 향상되어 침습적 조직 채취를 대체할 수 있는 현실적인 대안으로 주목받고 있습니다. 정밀의료와 맞춤치료에 대한 관심이 높아지는 가운데, 종양 혈액검사가 치료 반응, 내성 기전, 질병 진행을 전례 없는 정확도로 실시간으로 모니터링할 수 있게 되면서 시장 성장이 더욱 가속화되고 있습니다. 그러나 첨단 검사 플랫폼에 따른 높은 비용, 많은 지역에서 보험 적용 범위의 제한, 새로운 진단 기술을 둘러싼 규제의 복잡성 등 여러 가지 제약이 존재합니다.
또한 서로 다른 의료 시스템 간에 표준화된 프로토콜, 품질관리 조치, 임상 가이드라인이 부족하여 도입에 어려움을 겪을 수 있으며, 보급을 방해할 수 있습니다. 이러한 제약에도 불구하고 조기 암 검진 프로그램에서의 적용 범위 확대, 진단 정확도 향상을 위한 인공지능(AI) 및 머신러닝 플랫폼과의 통합, 연구개발에 대한 투자 증가를 통해 큰 기회가 창출되고 있습니다. 제약사, 진단기기 제조업체, 의료기관 간의 협력 강화는 특히 기존 생검 인프라가 제한적이면서도 암 진단 수요가 급성장하고 있는 신흥 경제국에서 시장 확대의 큰 잠재력을 가지고 있습니다.
본 조사의 주요 특징
- 이 보고서는 2024년을 기준 연도로 하여 예측 기간(2025-2032년) 시장 규모(10억 달러)와 예측 기간(2025-2032년)의 연평균 성장률(CAGR%)을 제시하는 종양 혈액 검사에 대한 상세한 분석 정보를 제공합니다.
- 또한 각 부문의 잠재적 매출기회를 밝히고, 이 시장의 매력적인 투자 제안 매트릭스에 대해 설명합니다.
- 시장 성장 촉진요인, 제약요인, 기회, 신제품 출시 또는 승인, 시장 동향, 지역별 전망, 주요 업체들의 경쟁 전략에 대한 중요한 정보를 제공합니다.
- 이 보고서는 기업 개요, 제품 포트폴리오, 주요 특징, 재무 성과, 전략 등 다양한 매개 변수를 기반으로 전 세계 종양 혈액 검사 시장의 주요 업체를 프로파일링합니다.
- 이 보고서는 마케팅 담당자 및 기업 경영진이 향후 제품 출시, 유형 업그레이드, 시장 확대, 마케팅 전략에 대한 정보에 입각한 의사결정을 내릴 수 있도록 돕습니다.
- 이 세계 종양 혈액 검사 시장 보고서는 투자자, 공급업체, 제품 제조업체, 유통업체, 신규 시장 진출기업, 재무 분석가 등 이 업계의 다양한 이해관계자를 대상으로 합니다.
- 이해관계자들은 세계 종양 혈액 검사 시장 분석에 사용되는 다양한 전략 매트릭스를 통해 의사결정을 쉽게 내릴 수 있습니다.
목차
제1장 조사 목적과 전제조건
- 조사 목적
- 전제조건
- 약어
제2장 시장 범위
- 리포트 개요
- 시장 정의와 범위
- 개요
제3장 시장 역학, 규제 및 동향 분석
- 시장 역학
- 촉진요인
- 억제요인
- 기회
- 영향 분석
- 주요 발전
- 규제 환경
- 제품 발매·승인
- PEST 분석
- Porter의 산업 분석
- 합병·인수의 동향
- 업계 동향
제4장 세계의 종양 혈액검사 시장 : 바이오마커 유형별, 2020-2032년
- 순환 종양 DNA(ctDNA)
- 순환종양세포(CTCs)
- 세포외소포(EVs)/엑소좀
- 기타 세포 유리 핵산
제5장 세계 종양 혈액검사 시장 : 기술별, 2020-2032년
- 중합효소 연쇄 반응(PCR) 기반 검사
- 차세대 시퀀싱(NGS)
- 마이크로어레이 기반 검사
- 질량분석법
- 면역측정법
제6장 세계의 종양 혈액검사 시장 : 임상 응용별, 2020-2032년
- 조기 발견/암검진
- 진단
- 치료 선택
- 치료 모니터링
- 미세잔존질환(MRD) 검출
- 재발 모니터링/예후
제7장 세계의 종양 혈액검사 시장 : 암 유형별, 2020-2032년
- 폐암
- 유방암
- 대장암
- 전립선암
- 방광암
- 악성 흑색종
- 기타 암(예 : 난소암, 췌장암, 백혈병, 림프종)
제8장 세계의 종양 혈액검사 시장 : 최종사용자별, 2020-2032년
- 병원
- 전문 클리닉
- 진단 검사실
- 학술·연구기관
- 제약·바이오테크놀러지 기업
제9장 세계의 종양 혈액검사 시장 : 지역별, 2020-2032년
- 북미
- 미국
- 캐나다
- 라틴아메리카
- 브라질
- 아르헨티나
- 멕시코
- 기타 라틴아메리카 국가
- 유럽
- 독일
- 영국
- 스페인
- 프랑스
- 이탈리아
- 러시아
- 기타 유럽
- 아시아태평양
- 중국
- 인도
- 일본
- 호주
- 한국
- ASEAN
- 기타 아시아태평양
- 중동
- GCC 국가
- 이스라엘
- 기타 중동 국가
- 아프리카
- 남아프리카
- 북아프리카
- 중앙아프리카
제10장 경쟁 구도
- Hoffmann-La Roche Ltd.
- Illumina, Inc.
- Guardant Health
- Bio-Rad Laboratories
- Abbott Laboratories
- Qiagen
- Agilent Technologies
- Thermo Fisher Scientific
- Siemens Healthineers
- GE Healthcare
- BD(Becton, Dickinson and Company)
- PerkinElmer
- Myriad Genetics
- Sysmex Corporation
- Danaher Corporation
제11장 애널리스트의 권장사항
- 기회
- 애널리스트의 견해
- Coherent Opportunity Map
제12장 참고 문헌 및 조사 방법
- 참고 문헌
- 조사 방법
- 출판사 소개
Tumor Blood Testing Market is estimated to be valued at USD 9.34 Bn in 2025 and is expected to reach USD 23.81 Bn by 2032, growing at a compound annual growth rate (CAGR) of 14.3% from 2025 to 2032.
| Report Coverage | Report Details | ||
|---|---|---|---|
| Base Year: | 2024 | Market Size in 2025: | USD 9.34 Bn |
| Historical Data for: | 2020 To 2024 | Forecast Period: | 2025 To 2032 |
| Forecast Period 2025 to 2032 CAGR: | 14.30% | 2032 Value Projection: | USD 23.81 Bn |
The global tumor blood testing market represents a transformative segment within the broader oncology diagnostics landscape, fundamentally reshaping how cancer detection, monitoring, and treatment decisions are approached in modern healthcare.
Tumor blood testing, also known as liquid biopsy, encompasses a revolutionary array of non-invasive diagnostic techniques that analyze circulating tumor cells (CTCs), circulating tumor DNA (ctDNA), exosomes, and other tumor-derived biomarkers present in peripheral blood samples.
This innovative approach offers significant advantages over traditional tissue-based biopsies, including reduced patient discomfort, lower procedural risks, real-time monitoring capabilities, and the ability to capture tumor heterogeneity more comprehensively. The market encompasses various applications ranging from early cancer screening and diagnosis to treatment selection, therapeutic monitoring, and minimal residual disease detection.
With advancing genomic sequencing technologies, artificial intelligence integration, and growing clinical evidence supporting liquid biopsy efficacy, the tumor blood testing market is experiencing unprecedented growth momentum. The increasing prevalence of cancer globally, coupled with rising demand for precision medicine approaches and personalized treatment strategies, continues to drive market expansion across diverse healthcare settings worldwide.
Market Dynamics
The global tumor blood testing market is propelled by several compelling drivers that underscore its rapid expansion and clinical adoption. The primary growth driver stems from the increasing global cancer burden, with rising incidence rates necessitating more efficient, accessible, and patient-friendly diagnostic solutions that can facilitate early detection and continuous monitoring throughout treatment journeys.
Technological advancements in next-generation sequencing, digital PCR, and molecular profiling techniques have significantly enhanced the sensitivity and specificity of liquid biopsies, making them increasingly viable alternatives to invasive tissue sampling procedures. The growing emphasis on precision medicine and personalized treatment approaches further accelerates market growth, as tumor blood testing enables real-time monitoring of treatment response, resistance mechanisms, and disease progression with unprecedented accuracy. However, the market faces notable restraints including high costs associated with advanced testing platforms, limited reimbursement coverage in many regions, and regulatory complexities surrounding novel diagnostic technologies.
Additionally, the lack of standardized protocols, quality control measures, and clinical guidelines across different healthcare systems creates implementation challenges that may hinder widespread adoption. Despite these constraints, substantial opportunities emerge through expanding applications in early-stage cancer screening programs, integration with artificial intelligence and machine learning platforms for enhanced diagnostic accuracy, and growing investments in research and development activities. The increasing collaboration between pharmaceutical companies, diagnostic manufacturers, and healthcare institutions presents significant potential for market expansion, particularly in emerging economies where traditional biopsy infrastructure remains limited but demand for cancer diagnostics continues to grow exponentially.
Key Features of the Study
- This report provides in-depth analysis of the global tumor blood testing market, and provides market size (USD Billion) and compound annual growth rate (CAGR%) for the forecast period (2025-2032), considering 2024 as the base year
- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players
- It profiles key players in the global tumor blood testing market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
- Key companies covered as a part of this study include F. Hoffmann-La Roche Ltd., Illumina, Inc., Guardant Health, Bio-Rad Laboratories, Abbott Laboratories, Qiagen, Agilent Technologies, Thermo Fisher Scientific, Siemens Healthineers, GE Healthcare, BD (Becton, Dickinson and Company), PerkinElmer, Myriad Genetics, Sysmex Corporation, and Danaher Corporation
- Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
- The global tumor blood testing market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global tumor blood testing market
Market Segmentation
- Biomarker Type Insights (Revenue, USD Bn, 2020 - 2032)
- Circulating Tumor DNA (ctDNA)
- Circulating Tumor Cells (CTCs)
- Extracellular Vesicles (EVs) / Exosomes
- Other Cell-Free Nucleic Acids
- Technology Insights (Revenue, USD Bn, 2020 - 2032)
- Polymerase Chain Reaction (PCR)-Based Testing
- Next-Generation Sequencing (NGS)
- Microarray-Based Testing
- Mass Spectrometry
- Immunoassays
- Clinical Application Insights (Revenue, USD Bn, 2020 - 2032)
- Early Detection/Cancer Screening
- Diagnosis
- Therapy Selection
- Treatment Monitoring
- Minimal Residual Disease (MRD) Detection
- Recurrence Monitoring/Prognosis
- Cancer Type Insights (Revenue, USD Bn, 2020 - 2032)
- Lung Cancer
- Breast Cancer
- Colorectal Cancer
- Prostate Cancer
- Bladder Cancer
- Melanoma
- Other Cancers (e.g., Ovarian, Pancreatic, Leukemia, Lymphoma)
- End User Insights (Revenue, USD Bn, 2020 - 2032)
- Hospitals
- Specialty Clinics
- Diagnostic Laboratories
- Academic and Research Institutes
- Pharmaceutical and Biotechnology Companies
- Regional Insights (Revenue, USD Bn, 2020 - 2032)
- North America
- U.S.
- Canada
- Latin America
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- South Africa
- North Africa
- Central Africa
- Key Players Insights
- Hoffmann-La Roche Ltd.
- Illumina, Inc.
- Guardant Health
- Bio-Rad Laboratories
- Abbott Laboratories
- Qiagen
- Agilent Technologies
- Thermo Fisher Scientific
- Siemens Healthineers
- GE Healthcare
- BD (Becton, Dickinson and Company)
- PerkinElmer
- Myriad Genetics
- Sysmex Corporation
- Danaher Corporation
Table of Contents
1. Research Objectives and Assumptions
- Research Objectives
- Assumptions
- Abbreviations
2. Market Purview
- Report Description
- Market Definition and Scope
- Executive Summary
- Global Tumor Blood Testing Market, By Biomarker Type
- Global Tumor Blood Testing Market, By Technology
- Global Tumor Blood Testing Market, By Clinical Application
- Global Tumor Blood Testing Market, By Cancer Type
- Global Tumor Blood Testing Market, By End User
- Global Tumor Blood Testing Market, By Region
3. Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Driver
- Restraint
- Opportunity
- Impact Analysis
- Key Developments
- Regulatory Scenario
- Product Launches/Approvals
- PEST Analysis
- PORTER's Analysis
- Merger and Acquisition Scenario
- Industry Trends
4. Global Tumor Blood Testing Market, By Biomarker Type, 2020-2032, (USD Bn)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
- Circulating Tumor DNA (ctDNA)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Circulating Tumor Cells (CTCs)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Extracellular Vesicles (EVs) / Exosomes
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Other Cell-Free Nucleic Acids
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
5. Global Tumor Blood Testing Market, By Technology, 2020-2032, (USD Bn)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
- Polymerase Chain Reaction (PCR)-Based Testing
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Next-Generation Sequencing (NGS)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Microarray-Based Testing
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Mass Spectrometry
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Immunoassays
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
6. Global Tumor Blood Testing Market, By Clinical Application, 2020-2032, (USD Bn)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
- Early Detection/Cancer Screening
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Diagnosis
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Therapy Selection
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Treatment Monitoring
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Minimal Residual Disease (MRD) Detection
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Recurrence Monitoring/Prognosis
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
7. Global Tumor Blood Testing Market, By Cancer Type, 2020-2032, (USD Bn)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
- Lung Cancer
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Breast Cancer
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Colorectal Cancer
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Prostate Cancer
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Bladder Cancer
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Melanoma
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Other Cancers (e.g., Ovarian, Pancreatic, Leukemia, Lymphoma)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
8. Global Tumor Blood Testing Market, By End User, 2020-2032, (USD Bn)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
- Hospitals
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Specialty Clinics
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Diagnostic Laboratories
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Academic and Research Institutes
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Pharmaceutical and Biotechnology Companies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
9. Global Tumor Blood Testing Market, By Region, 2020 - 2032, Value (USD Bn)
- Introduction
- Market Share (%) Analysis, 2025, 2028 & 2032, Value (USD Bn)
- Market Y-o-Y Growth Analysis (%), 2021 - 2032, Value (USD Bn)
- Regional Trends
- North America
- Introduction
- Market Size and Forecast, By Biomarker Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Technology, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Clinical Application, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Cancer Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By End User, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
- U.S.
- Canada
- Latin America
- Introduction
- Market Size and Forecast, By Biomarker Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Technology, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Clinical Application, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Cancer Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By End User, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Introduction
- Market Size and Forecast, By Biomarker Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Technology, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Clinical Application, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Cancer Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By End User, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- Introduction
- Market Size and Forecast, By Biomarker Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Technology, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Clinical Application, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Cancer Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By End User, 2020 - 2032, Value (USD Bn)
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- Introduction
- Market Size and Forecast, By Biomarker Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Technology, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Clinical Application, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Cancer Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By End User, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- Introduction
- Market Size and Forecast, By Biomarker Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Technology, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Clinical Application, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Cancer Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By End User, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Country/Region, 2020 - 2032, Value (USD Bn)
- South Africa
- North Africa
- Central Africa
10. Competitive Landscape
- Hoffmann-La Roche Ltd.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Illumina, Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Guardant Health
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Bio-Rad Laboratories
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Abbott Laboratories
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Qiagen
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Agilent Technologies
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Thermo Fisher Scientific
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Siemens Healthineers
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- GE Healthcare
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- BD (Becton, Dickinson and Company)
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- PerkinElmer
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Myriad Genetics
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Sysmex Corporation
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Danaher Corporation
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
11. Analyst Recommendations
- Wheel of Fortune
- Analyst View
- Coherent Opportunity Map
12. References and Research Methodology
- References
- Research Methodology
- About us
